Dermatologic Manifestation of Acro-Ischemia Associated With COVID-19

REFERENCES

1. 1.↵
   1. Wu T,
   2. Zuo Z,
   3. Kang S,
   4. et al.

   Multi-organ dysfunction in patients with COVID-19: a systematic review and meta-analysis. Aging Dis. 2020;11(4):874-894. doi: 10.14336/AD.2020.0520

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Diaz-Guimaraens B,
   2. Dominguez-Santas M,
   3. Suarez-Valle A,
   4. et al.

   Petechial skin rash associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol. 2020;156(7):820-822. doi: 10.1001/jamadermatol.2020.1741

   OpenUrlCrossRef
3. 3.
   1. van Damme C,
   2. Berlingin E,
   3. Saussez S,
   4. Accaputo O

   . Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(7):e300-e301. doi: 10.1111/jdv.16523

   OpenUrlCrossRef
4. 4.↵
   1. García-Legaz Martínez M,
   2. Martínez-Doménech Á,
   3. Magdaleno-Tapial J,
   4. et al.

   Acute acral cutaneous manifestations during the COVID-19 pandemic: a single-centre experience. J Eur Acad Dermatol Venereol. 2020;34(11):e692-e694. doi: 10.1111/jdv.16777

   OpenUrlCrossRef
5. 5.↵
   1. Bouaziz JD,
   2. Duong TA,
   3. Jachiet M,
   4. et al.

   Vascular skin symptoms in COVID-19: a French observational study. J Eur Acad Dermatol Venereol. 2020;34(9):e451-e452. doi: 10.1111/jdv.16544

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Zhang Y,
   2. Cao W,
   3. Xiao M,
   4. et al.

   Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Article in Chinese. Zhonghua Xue Ye Xue Za Zhi. 2020;41(0):E006. doi: 10.3760/cma.j.issn.0253-2727.2020.0006

   OpenUrlCrossRef
7. 7.
   1. Alramthan A,
   2. Aldaraji W

   . Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East. Clin Exp Dermatol. 2020;45(6):746-748. doi: 10.1111/ced.14243

   OpenUrlCrossRef
8. 8.
   1. Mazzotta F,
   2. Troccoli T

   . Acute acro-ischemia in the child at the time of COVID-19. Eur J Pediatr Dermatol. 2020;30(2):71-74. doi: 10.26326/2281-9649.30.2.2102

   OpenUrlCrossRef
9. 9.↵
   1. Calvão J,
   2. Relvas M,
   3. Pinho A,
   4. Brinca A,
   5. Cardoso JC

   . Acro-ischaemia and COVID-19 infection: clinical and histopathological features. J Eur Acad Dermatol Venereol. 2020;34(11):e653-e754. doi: 10.1111/jdv.16687

   OpenUrlCrossRef
10. 10.↵
    1. Freeman EE,
    2. McMahon DE,
    3. Lipoff JB,
    4. et al.

    The spectrum of COVID-19–associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118-1129. doi: 10.1016/j.jaad.2020.06.1016

    OpenUrlCrossRef
11. 11.↵
    1. Sachdeva M,
    2. Gianotti R,
    3. Shah M,
    4. et al.

    Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermatol Sci. 2020;98(2):75-81. doi: 10.1016/j.jdermsci.2020.04.011

    OpenUrlCrossRef
12. 12.↵
    1. Criado PR,
    2. Abdalla BMZ,
    3. de Assis IC,
    4. van Blarcum de Graaff Mello C,
    5. Caputo GC,
    6. Vieira IC

    . Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms. Inflamm Res. 2020;69(8):745-756. doi: 10.1007/s00011-020-01370-w

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Wollina U,
    2. Karadağ AS,
    3. Rowland-Payne C,
    4. Chiriac A,
    5. Lotti T

    . Cutaneous signs in COVID-19 patients: a review. Dermatol Ther. 2020;33(5):e13549. doi: 10.1111/dth.13549

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Martini R

    . The compelling arguments for the need of microvascular investigation in COVID-19 critical patients. Clin Hemorheol Microcirc. 2020;75(1):27-34. doi: 10.3233/CH-200895

    OpenUrlCrossRef
15. 15.
    1. Guarneri C,
    2. Venanzi Rullo E,
    3. Gallizzi R,
    4. Ceccarelli M,
    5. Cannavò SP,
    6. Nunnari G

    . Diversity of clinical appearance of cutaneous manifestations in the course of COVID-19. J Eur Acad Dermatol Venereol. 2020;34(9):e449-e450. doi: 10.1111/jdv.16669

    OpenUrlCrossRef
16. 16.
    1. Askin O,
    2. Altunkalem RN,
    3. Altinisik DD,
    4. Uzuncakmak TK,
    5. Tursen U,
    6. Kutlubay Z

    . Cutaneous manifestations in hospitalized patients diagnosed as COVID-19. Dermatol Ther. 2020;33(6):e13896. doi: 10.1111/dth.13896

    OpenUrlCrossRefPubMed
17. 17.
    1. Magro C,
    2. Mulvey JJ,
    3. Berlin D,
    4. et al.

    Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1-13. doi: 10.1016/j.trsl.2020.04.007

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Zhang Y,
    2. Xiao M,
    3. Zhang S,
    4. et al.

    Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382(17):e38. doi: 10.1056/NEJMc2007575

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Arakaki R,
    2. Fox L

    . Updates in the approach to the patient with purpura. Curr Dermatol Rep. 2017;6:55-62. doi: 10.1007/s13671-017-0184-7

    OpenUrlCrossRef